Table 2.
Characteristics of the study subjects
| Variable | N = 119 |
|---|---|
| Age | 30.6 ± 8.8 |
| BMI [kg/m2] | 21.63 ± 3.2 |
| Sex male [%] | 85 (71.4%) |
| Smoking | 2 (1.7%) |
| Alcohol | 7 (5.8%) |
| Residence City [%] | 87 (73.1%) |
| Disease activity level | |
| Remission | 92 (77.3%) |
| Mild active | 24 (20.2%) |
| Moderate active | 3 (2.5%) |
| Severe active | 0 (0%) |
| Current medications | |
| Mesalazine | 3 (2.5%) |
| Immunosuppressives | 2 (1.7%) |
| Biologicals | 95 (79.8%) |
| Immunosuppressives + biologicals | 16 (13.4%) |
| Others | 3 (2.5%) |
| GPAQ (MET-mins/wk) | Median (Q1; Q3) |
| Work | |
| Vigorous | 0 (0; 0) |
| Moderate | 0 (0; 0) |
| Total Work MVPA | 0 (0; 488) |
| Travel | |
| Moderate | 120 (0; 480) |
| Recreation | |
| Vigorous | 0 (0; 120) |
| Moderate | 120 (0; 480) |
| Total Recreation MVPA | 240 (0; 720) |
| GPAQ Total MVPA | 944 (240; 1920) |
| Sedentary mins/day | 360 (210; 450) |
| PROMIS-57 T Score | Mean (SD) |
| Physical functioning | 50.49 ± 8.95 |
| Anxiety | 49.23 ± 9.33 |
| Depression | 49.28 ± 9.58 |
| Fatigue | 49.36 ± 9.60 |
| Sleep disturbance | 49.92 ± 9.49 |
| Ability to participate in social roles | 49.29 ± 9.65 |
| Pain interference | 1.03 ± 1.52 |
| Pain intensity | 49.31 ± 8.73 |
The results are expressed as numbers (%), medians (Q1:Q3) and means (SDs). BMI: body mass index, MVPA: moderate and vigorous physical activity